Skip to content
OpenCapital
Get started

Xenon Pharmaceuticals XENE Fair Value Of Stock Options Exercised On Cashless Basis

Other financials

Income statement

See full
Revenue--100%
Operating income-$112.3M-54.4%
Net income-$102.3M-57.3%
EPS (diluted)-$1.17-41.0%

Balance sheet

See full
Cash & equivalents$545.9M+368%
Total debt$7.5M-13.6%
Total equity$1.3B+90.0%
Total assets$1.4B+86.6%

Cash flow

See full
Operating cash flow-$88.9M-44.2%
CapEx$133.0K+209%
Free cash flow-$89.0M-44.3%

Valuation

See full
Market cap$5.11B+116%

Profitability

See full
Operating margin-4,974.3%—
Net margin-4,612.1%—
FCF margin-3,732.2%—

Returns & leverage

See full
Return on equity-37.5%+8.7pp
Debt / equity0×0.0×
Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept xene:FairValueOfStockOptionsExercisedOnCashlessBasis.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Xenon Pharmaceuticals's fair value of stock options exercised on cashless basis?
Xenon Pharmaceuticals (XENE) reported fair value of stock options exercised on cashless basis of $17.64M in Q1 2026.
How has Xenon Pharmaceuticals's fair value of stock options exercised on cashless basis changed year-over-year?
Xenon Pharmaceuticals's fair value of stock options exercised on cashless basis increased by 746.2% year-over-year, from $2.09M to $17.64M.
What is the long-term trend for Xenon Pharmaceuticals's fair value of stock options exercised on cashless basis?
Over 3 years (2021 to 2024), Xenon Pharmaceuticals's fair value of stock options exercised on cashless basis has grown at a 35.4% compound annual growth rate (CAGR), from $3.35M to $8.31M.